Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
Want to see BVNRY full AI Analyst Report?
Earnings Data
Report Date
Aug 21, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.24Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple clear positives: solid Q1 revenue (DKK 1.058b), Travel Health growth (14%), successful global rollout of Vimkunya with DKK 41m in Q1, a meaningful BARDA order that completed a long-term freeze-dried contract and led management to raise full-year revenue guidance to DKK 5.5–5.7b and EBITDA margin to ~28%. Management highlighted strong manufacturing performance, secured Public Preparedness revenues (DKK 2.0b secured with DKK 300–500m expected more), and progress on key R&D readouts (Phase II cell-line interim data due later in 2026). The principal negatives are operational timing risks and one-off cash outflows: U.S. regulatory/publication delays (CDC MMWR) creating headwinds for U.S. uptake of Vimkunya, Encepur inventory/shelf-life timing effects that pressured reported Q1 product sales (though market share and market growth are healthy), negative Q1 operating cash flow impacted by milestone payments, and staged pipeline advancement. Overall, positives (raised guidance, contract wins, product rollouts and strong Travel Health metrics) appear to outweigh the manageable and largely timing-related lowlights.Company Guidance
Strong Q1 Revenue and Improved Full-Year Guidance
Total Q1 revenue DKK 1.058 billion (Public Preparedness DKK 294m; Travel Health DKK 721m). Company raised 2026 revenue guidance to DKK 5.5–5.7 billion and increased EBITDA margin target to ~28% (up from 25%).
Travel Health Growth and Product Momentum
Travel Health grew 14% in Q1 (14% when excluding discontinued partner revenue; 6% on headline basis). Rabies demand strong with U.S. market growth ~23% and Germany ~29%. Vivotif (typhoid) showing recovery with +12% this quarter. Encepur (TBE) market grew ~12% and Bavarian Nordic gained ~1 percentage point market share in the period.
Vimkunya Launch Progress
Vimkunya (chikungunya) launched in ~14 countries (U.S., Europe, U.K., Belgium, Netherlands, Switzerland approval secured; Health Canada approval expected H1). Q1 revenue DKK 41m and management reiterates 2026 guidance of DKK 250m for the product.
Public-Private Contract Wins and BARDA Order
New BARDA order announced (USD 97m) completing parts of an 11.5 million dose freeze-dried contract. Since 2017, orders >USD 1.2 billion under this contract. Management secured DKK 2.0 billion in Public Preparedness revenue and expects an additional DKK 300–500m for 2026, leading to increased Public Preparedness guidance to DKK 2.3–2.5 billion.
Profitability and Manufacturing Performance
Q1 EBITDA margin 16% (EBITDA DKK 165m), in line with Q1 seasonality expectations; gross margin 45%. Manufacturing yields and site performance reported as strong and increasingly routine, supporting margin outlook for the year.
R&D Focus and Pipeline Milestones
Major R&D spending focused on lifecycle management for chikungunya (pediatric, booster, efficacy studies) and a Phase II cell-line transition study (interim data expected later in 2026). DoD-funded equine encephalitis program progressing; early-stage Lyme and EBV programs advancing but staged.
Balance Sheet & Capital Allocation
Cash balance ~DKK 2.3 billion at quarter end (~DKK 2.2b post remaining share buyback). Completed ~DKK 350m of a DKK 500m share buyback to date. Management confirms capital allocation policy: pursue attractive M&A opportunities first, otherwise return cash via buybacks.
BVNRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BVNRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $10.39 | $9.83 | -5.31% |
Mar 12, 2026 | $9.45 | $9.13 | -3.34% |
Nov 14, 2025 | $9.72 | $9.14 | -5.94% |
Aug 22, 2025 | $12.38 | $12.49 | +0.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bavarian Nordic A/S (BVNRY) report earnings?
Bavarian Nordic A/S (BVNRY) is schdueled to report earning on Aug 21, 2026, Before Open (Confirmed).
What is Bavarian Nordic A/S (BVNRY) earnings time?
Bavarian Nordic A/S (BVNRY) earnings time is at Aug 21, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BVNRY EPS forecast?
Currently, no data Available